Research programme: glutamate antagonists - Vernalis
Alternative Names: glutamate antagonists research programme - VernalisLatest Information Update: 17 Oct 2018
At a glance
- Originator Vernalis
- Class
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Neuropathic pain
Most Recent Events
- 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
- 24 Apr 2007 Discontinued - Preclinical for Neuropathic pain in United Kingdom (unspecified route)
- 03 Oct 2003 Vernalis Group has merged with British Biotech to form Vernalis